Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis
- PMID: 30366160
- DOI: 10.1016/j.hrthm.2018.10.022
Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis
Abstract
Background: More sustained forms of atrial fibrillation (AF) are less amenable to treatment and associated with worse outcomes, but the incidence and predictors of AF progression are not well defined.
Objective: The purpose of this study was to perform a systematic review and meta-analysis assessing the incidence and predictors of AF progression.
Methods: PubMed, EMBASE, and the Cochrane Library were searched from inception to August 2017. AF progression was defined as progression from paroxysmal to persistent/permanent AF or as progression from persistent to permanent AF. Random effect models were used to calculate pooled cumulative incidence rates. Predictors related to between-study variability were assessed using meta-regression analyses.
Results: We identified 47 studies with 27,266 patients who were followed for 105,912 patient-years. The pooled incidence of AF progression was 8.1 per 100 patient-years of follow-up (95% confidence interval [CI] 7.1-9.1 per 100 patient-years of follow-up; I2 = 98%; P < .0001). The incidence was 7.1 per 100 patient-years of follow-up (95% CI 6.2-8.0 per 100 patient-years of follow-up; across 42 studies) for progression from paroxysmal to non-paroxysmal AF as compared with 18.6 per 100 patient-years of follow-up (95% CI 8.9-28.3 per 100 patient-years of follow-up; across 5 studies) for progression from persistent to permanent AF. Higher age (β = 5.4; 95% CI 1.4-9.4; P = .01; R2 = 14.3%) and the prevalence of hypertension (β = 5.2; 95% CI 1.0-9.4; P = .02; R2 = 18.0%) were associated with a higher AF progression rate. Follow-up duration (β = -4.5; 95% CI -5.8 to -3.3; P < .0001; R2 = 68.0%) and the prevalence of paroxysmal AF (β = -9.5; 95% CI -18.7 to -0.3; P = .04; R2 = 4.4%) were inversely associated with AF progression. Together these variables explained 73.8% of the observed between-study heterogeneity.
Conclusion: The incidence of AF progression appears to be relatively low, and the incidence seems to decrease with longer follow-up duration. Age, hypertension, baseline AF type, and follow-up duration explained a high percentage of the observed between-study heterogeneity.
Keywords: Atrial fibrillation; Meta-analysis; Paroxysmal atrial fibrillation; Persistent atrial fibrillation; Progression.
Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation.Heart Rhythm. 2017 Jun;14(6):801-807. doi: 10.1016/j.hrthm.2017.01.038. Epub 2017 Feb 21. Heart Rhythm. 2017. PMID: 28232263
-
Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation.Circ Arrhythm Electrophysiol. 2014 Apr;7(2):267-73. doi: 10.1161/CIRCEP.113.000471. Epub 2014 Mar 7. Circ Arrhythm Electrophysiol. 2014. PMID: 24610740
-
Prevalence and predictors of atrial fibrillation type among individuals with recent onset of atrial fibrillation.Swiss Med Wkly. 2018 Sep 23;148:w14652. doi: 10.4414/smw.2018.14652. eCollection 2018 Sep 10. Swiss Med Wkly. 2018. PMID: 30378644
-
Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis.Cardiovasc Diabetol. 2021 Dec 7;20(1):230. doi: 10.1186/s12933-021-01423-2. Cardiovasc Diabetol. 2021. PMID: 34876114 Free PMC article.
-
Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis.Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2756-2765. doi: 10.1016/j.numecd.2021.05.034. Epub 2021 Jun 18. Nutr Metab Cardiovasc Dis. 2021. PMID: 34348878
Cited by
-
Factors Associated with Progression of Atrial Fibrillation and Impact on All-Cause Mortality in a Cohort of European Patients.J Clin Med. 2023 Jan 18;12(3):768. doi: 10.3390/jcm12030768. J Clin Med. 2023. PMID: 36769416 Free PMC article.
-
Comparison of the Efficacy of Atorvastatin and Rosuvastatin in Preventing Atrial Fibrillation after Coronary Artery Bypass Grafting: A Double-Blind Randomized Comparative Trial.J Tehran Heart Cent. 2023 Apr;18(2):115-121. doi: 10.18502/jthc.v18i2.13321. J Tehran Heart Cent. 2023. PMID: 37637286 Free PMC article.
-
Genetically-determined body mass index and the risk of atrial fibrillation progression in men and women.PLoS One. 2021 Feb 18;16(2):e0246907. doi: 10.1371/journal.pone.0246907. eCollection 2021. PLoS One. 2021. PMID: 33600500 Free PMC article.
-
Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study.Europace. 2024 Aug 30;26(9):euae218. doi: 10.1093/europace/euae218. Europace. 2024. PMID: 39150084 Free PMC article.
-
Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis.Front Cardiovasc Med. 2022 May 9;9:833329. doi: 10.3389/fcvm.2022.833329. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35615562 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical